Reasons for non-recruitment of eligible patients to a randomised controlled trial of secondary prevention after intracerebral haemorrhage: observational study.

Trials 2017 04 5;18(1):162. Epub 2017 Apr 5.

Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.

Background: Recruitment to randomised prevention trials is challenging, not least for intracerebral haemorrhage (ICH) associated with antithrombotic drug use. We investigated reasons for not recruiting apparently eligible patients at hospital sites that keep screening logs in the ongoing REstart or STop Antithrombotics Randomised Trial (RESTART), which seeks to determine whether to start antiplatelet drugs after ICH.

Method: By the end of May 2015, 158 participants had been recruited at 108 active sites in RESTART. The trial coordinating centre invited all sites that kept screening logs to submit screening log data, followed by one reminder. We checked the integrity of data, focused on the completeness of data about potentially eligible patients and categorised the reasons they were not randomised.

Results: Of 108 active sites, 39 (36%) provided usable screening log data over a median of ten (interquartile range = 5-13) months of recruitment per site. During this time, sites screened 633 potentially eligible patients and randomised 53 (8%) of them. The main reasons why 580 patients were not randomised were: 43 (7%) patients started anticoagulation, 51 (9%) patients declined, 148 (26%) patients' stroke physicians were not uncertain about using antiplatelet drugs, 162 (28%) patients were too unwell and 176 (30%) patients were not randomised due to other reasons.

Conclusion: RESTART recruited ~8% of eligible patients. If more physicians were uncertain about the therapeutic dilemma that RESTART is addressing, RESTART could have recruited up to four times as many participants. The trial coordinating centre continues to engage with physicians about their uncertainty.

Trial Registration: EU Clinical Trials, EudraCT 2012-003190-26 . Registered on 3 July 2012.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-017-1909-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382439PMC
April 2017
49 Reads

Publication Analysis

Top Keywords

eligible patients
20
patients randomised
16
patients
10
restart recruited
8
108 active
8
active sites
8
screening logs
8
sites screening
8
antiplatelet drugs
8
physicians uncertain
8
intracerebral haemorrhage
8
log data
8
coordinating centre
8
trial coordinating
8
screening log
8
randomised
6
restart
6
eligible
5
sites
5
ten interquartile
4

References

(Supplied by CrossRef)

C Tudur Smith et al.
Trials. 2014

R Al-Shahi Salman et al.
Lancet. 2014

MK Campbell et al.
Health Technol Assess. 2007

BG Sully et al.
Trials. 2013

AF Fonville et al.
Stroke. 2013

AM McDonald et al.
Trials. 2006

FJ Slieker et al.
Neurosurgery. 2008

D St Germain et al.
J Oncol Pract. 2014

GM Duchesne et al.
J Med Imaging Radiat Oncol. 2010

CJ Asch van et al.
Lancet Neurol. 2010

PROGRESS Collaborative Group et al.
Lancet 2001

Similar Publications